Home Tags Antibody-drug Conjugates

Tag: Antibody-drug Conjugates

Mirvetuximab soravtansine Receives full FDA approval for use in treatment of...

Mirvetuximab soravtansine Receives full FDA approval for use in treatment of Certain Ovarian Cancer Patients

Pyxis Oncology to Prioritize Lead ADC Program

Clinical-stage Pyxis Oncology, a  company focused on developing antibody-drug conjugates (ADCs) and immune-oncology (IO) therapeutics to target difficult-to-treat cancers, is prioritizing the development of their investigational ADC, PYX-201,  a novel first-in-concept and first-in-class tumor stroma targeting ADC. Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024.

Tisotumab Vedotin Significantly Prolongs Overall Survival in Patients with Recurrent/Metastatic Cervical...

Results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin (Tivdak®; Seagen/Genmab)* demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy (HR: 0.70, 95% CI: 0.54-0.89, p=0.0038).[1]
San Diego Skyline from Coronado Island

World ADC San Diego 2023: What to Expect

The past few years saw significant progress in the  treatment of cancer and hematological malignancies through antibody-druf conjugates (ADCs), with numerous approvals and positive...

Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering

In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).

Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer

Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

ZB131 ADC Induce Potent Anti-tumor Activity CSP-expressing Tumors

Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).

A Fantastic Voyage: From Magic Bullet to Antibody-drug Conjugate

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer (and potentially other diseases). However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.

FDA Grants Fast Track Designation to DB-1303 for the Treatment of...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.